BATTAL Holding plans to establish the production of parenteral pharmaceuticals in Uzbekistan.

The company's annual revenue for 2022 is reported to be 200 million USD. Over the past five years, the company has shown an average financial growth of 15%. Its products are exported to more than 30 countries.

During the meeting, the importance of developing mutually beneficial relationships in six key areas was emphasized, including the pharmaceutical industry, as well as the necessity to explore international experiences and modern approaches in these fields.

The parties discussed the development of the healthcare system in Uzbekistan, particularly the creation of new projects in the pharmaceutical sector, the attraction of modern technologies, the localization of drug production, and the prospects for further mutual cooperation.

Additionally, a Memorandum of Understanding was signed during the meeting between BATTAL Holding and the Agency for the Development of the Pharmaceutical Industry of Uzbekistan for the implementation of a project to produce parenteral medicines in Uzbekistan.

According to preliminary estimates by the foreign investor, the project will cost $30 million, which will create 500 jobs and produce 80 million units of medicines annually.

During the discussions, there was also an exchange of views on the activities of BATTAL Holding, its production scale, experience, and potential. As a result of the negotiations, the parties agreed on further development and strengthening of mutual relations, as well as on systematic and effective work to achieve the set goals.